A61P 15/04
Drugs for genital or sexual disorders: for inducing labour or abortion
Official title: for inducing labour or abortion; Uterotonics
A61P15/04 (Drugs for genital or sexual disorders: for inducing labour or abortion) appears on 289 US grants and 343 published applications in this corpus.
Search patents in A61P- Granted patents
- 289
- Published applications
- 343
- Assignees
- 201
- Inventors
- 864
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 6 | 0 |
| 1978 | 8 | 0 |
| 1979 | 0 | 0 |
| 1980 | 4 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 5 | 0 |
| 1997 | 3 | 0 |
| 1998 | 8 | 0 |
| 1999 | 2 | 0 |
| 2000 | 11 | 0 |
| 2001 | 10 | 1 |
| 2002 | 5 | 16 |
| 2003 | 7 | 15 |
| 2004 | 11 | 17 |
| 2005 | 5 | 20 |
| 2006 | 8 | 19 |
| 2007 | 11 | 22 |
| 2008 | 7 | 16 |
| 2009 | 9 | 11 |
| 2010 | 10 | 29 |
| 2011 | 12 | 21 |
| 2012 | 17 | 27 |
| 2013 | 22 | 23 |
| 2014 | 21 | 12 |
| 2015 | 9 | 16 |
| 2016 | 7 | 7 |
| 2017 | 6 | 14 |
| 2018 | 7 | 5 |
| 2019 | 7 | 12 |
| 2020 | 9 | 5 |
| 2021 | 6 | 12 |
| 2022 | 6 | 4 |
| 2023 | 2 | 7 |
| 2024 | 4 | 6 |
| 2025 | 4 | 5 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Medical use of tafoxiparin28 Apr 2026US 12,611,423 B2Dilafor AB
- Tafoxiparin for the treatment of preeclampsia23 Dec 2025US 12,502,403 B2Dilafor AB
- Liposomal composition containing mild acidic active agent23 Sep 2025US 12,419,837 B2Taiwan Liposome Co., Ltd.
- Medical use of tafoxiparin23 Sep 2025US 12,419,904 B2Dilafor AB
- 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels11 Mar 2025US 12,246,008 B2Merck Sharp & Dohme Corp.
- Microbiome-based informed method to formulate live biotherapeutics20 Aug 2026US 2026/0240920 A1University of Maryland, Baltimore
- Liposomal composition containing mild acidic active agent25 Dec 2025US 2025/0387332 A1Taiwan Liposome Co., Ltd.
- New medical use of tafoxiparin27 Nov 2025US 2025/0360160 A1
- Medical use of tafoxiparin5 Jun 2025US 2025/0177435 A1Dilafor AB
- Mifepristone oral form for its use in cervix ripening and labour induction8 May 2025US 2025/0144118 A1Nordic Group B.V.
Most cited
By later US patents
- Gum pad for delivery of medication to mucosal tissues1,140US 6,319,510 B12001
- Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates129US 8,088,387 B2ImmunoGen, Inc. · 2012
- Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles127US 8,101,209 B2Flamel Technologies · 2012
- FLT-4(FMS-like tyrosine kinase), FLT-15, variants thereof used as growth factor inhibitors82US 6,011,003 AMetris Therapeutics Limited · 2000
- Mucoadhesive pharmaceutical composition for the controlled release of active principles62US 5,900,247 AAdir et Compagnie · 1999